Alexander Spira, MD, PhD, FACP

Articles

Emerging Strategies for ALK+ NSCLC

December 5th 2025

Panelists discuss novel research directions aimed at overcoming resistance and extending survival in ALK-positive lung cancer.

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

December 5th 2025

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

Real-World Data in ALK+ NSCLC

November 26th 2025

Panelists discuss how real-world data complement clinical trials in understanding outcomes for ALK-positive lung cancer.

Using Long-Term Data to Guide ALK+ NSCLC Treatment

November 26th 2025

Panelists discuss how mature survival data inform treatment sequencing and maintenance strategies in ALK-positive lung cancer.

Investigational Therapies and Ongoing Trials in ROS1+ NSCLC

November 12th 2025

Panelists discuss ongoing research and investigational strategies aimed at overcoming resistance in ROS1-driven lung cancer.

Use of ROS1-Targeting Agents in Clinical Practice

November 12th 2025

Panelists discuss translating clinical trial evidence on ROS1-targeted therapy into real-world patient management.

ALK Alterations and Treatment Options for ALK+ NSCLC

November 5th 2025

Panelists discuss the role of ALK rearrangements in lung cancer and the development of successive generations of targeted inhibitors.

Long-Term Data in ALK+ NSCLC

November 5th 2025

Panelists discuss long-term data demonstrating the durability of response and intracranial protection achieved with modern ALK-targeted therapies.

Spotlight on ROS1-Targeted Therapies in Advanced NSCLC

November 5th 2025

Panelists discuss the molecular and clinical characteristics of ROS1-driven lung cancer and the role of precise molecular testing in guiding targeted therapy.

Treatment Options for ROS1+ Advanced NSCLC

November 5th 2025

Panelists discuss first-line treatment strategies for ROS1-positive lung cancer and the factors influencing therapy selection and sequencing.

Dr Spira Details Future Directions for Amivantamab in NSCLC

January 30th 2025

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

Dr Spira on RMC-9805 in KRAS G12D–Mutated Pancreatic Ductal Adenocarcinoma

January 24th 2025

Alexander I. Spira MD, PhD, FACP, FASCO, discusses data of RMC-9805 in previously treated, advanced KRAS G12D–mutated pancreatic ductal adenocarcinoma.

Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) With Biomarkers of High-Risk Disease: A Secondary Analysis From the Phase 3 MARIPOSA Study

June 19th 2024

A secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.

Dr Spira on the Evaluation of Fianlimab Plus Cemiplimab in Advanced Melanoma

October 4th 2023

Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.

Dr. Spira on the FDA Approval of Adagrasib in KRAS G12C–mutant NSCLC

December 12th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Looking Toward the Future Management of Non–Small Cell Lung Cancer

August 16th 2022

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

August 16th 2022

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Novel Therapy for NSCLC With ALK Rearrangements

August 9th 2022

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Novel Therapy for NSCLC With KRAS G12C Mutation

August 9th 2022

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC

August 8th 2022

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.